Korro Bio Inc. (KRRO) Sotuvning operatsion marjasi

Ommaviy kompaniya Korro Bio Inc. (KRRO) logotipi

Korro Bio, Inc. (KRRO) RNA tahrirlash sohasida mustahkam mavqega ega bo'lib, mutatsiyalarni xavfsiz tuzatish uchun OPERA platformasidan foydalanadi. Ushbu grafikda GURU.Markets ma'lumotlari aks etgan yakuniy operatsion marja -5796.00 joriy parametr qiymati ekanligini ko'rsatmoqda. Kompaniya o'zining faol o'sish bosqichida vaqtincha genomni tuzatish orqali noyob patologiyalar bozorini egallashni maqsad qilgan bo'lib, inqilobiy va qaytuvchi davolash usullarini taklif etmoqda.

Korro Bio, Inc (KRRO): Operatsion marja 21.02.2024dan 19.11.2026gacha

Korro Bio, Inc - tahliliy kesimlar va asosiy koʻrsatkichlar (KRRO)

- aksiya narxi va baholash bo'yicha konsensus prognoz:
Kompaniyaning fundamental tahlili:Korro Bio, Inc, KRRO
Korro Bio Inc. asosiy tovari

Operatsion marja soliqlar va foizlar to'lanishidan oldingi foyda ulushini o'lchash orqali asosiy biznesning samaradorligini belgilaydi. Ushbu ko'rsatkichdagi ijobiy dinamika investorga xarajatlarning optimallashtirilganligi va modelning kengayish imkoniyatlari oshganligi haqida signal beradi. Operatsion rentabellik tendentsiyasini tahlil qilish orqali aktivning real risk premiumini baholash mumkin. Korro Bio, Inc. (KRRO) uchun ushbu ko'rsatkich RNA tahrirlash terapiyasini tijoratlashtirishga o'tish davrida asosiy ahamiyatga ega bo'ladi. Klinik sinovlarning muvaffaqiyati joriy xarajatlarni sog'liqni saqlash sug'urta kompaniyalari bilan ko'p milliard dollarlik shartnomalarga aylantiradi.

Raqobatdosh kompaniyalar

Sotuvning operatsion marjasi TEM|QGEN - Operatsion foyda bo'yicha marjinallik|Operatsion marja IONS|RGEN - Sotuvning operatsion rentabelligi|Operatsion rentabellik Avidity RNA|Operatsion marja CRISPR Therapeutics Corp CRSP|GeneDx Corp - Operatsion marja|Ultragenyx Pharma (RARE) - Sotuvning operatsion marjasi|beamtx.com (BEAM) - Operatsion rentabellik|SRPT: Operatsion foyda koeffitsiyenti|Sotuvning operatsion marjasi TWST|TXG - Operatsion foyda bo'yicha marjinallik|Operatsion marja NTLA|Operatsion faoliyat rentabelligi Stoke Therapeutics|Operatsion rentabellik BioLife Solutions BLFS|Wave Life Sciences (WVE) - Sotuvning operatsion rentabelligi|Maze Therapeutics, Inc. - Operatsion marja|Operatsion faoliyat rentabelligi Sionna Therapeutics, Inc. SION|Prime Medicine Bio (PRME) - Operatsion rentabellik|TSHA: Operatsion foyda koeffitsiyenti|Operatsion rentabellik uniQure Pharma|MGTX - Operatsion foyda bo'yicha marjinallik|Operatsion marja RGNX|Operatsion rentabellik SLDB (Solid Biosciences)|Ocugen Corp - Sotuvning operatsion marjasi|PACB: Operatsion foyda bo'yicha sotuv rentabelligi|benitec.com - Operatsion marja|DSGN - Operatsion marja|RCKT: Operatsion marja|FDMT (4D Molecular Therapeutics Inc) - Operatsion rentabellik|Sotuvning operatsion marjasi LXEO|Sotuvning operatsion rentabelligi Editas EDIT|Operatsion marja SLN|ProQR Therapeutics - Operatsion foyda bo'yicha sotuv rentabelligi|Operatsion marja CDXS (Codexis, Inc.)|SGMO: Operatsion foyda bo'yicha sotuv rentabelligi|Nautilus Biotechnology - Operatsion marja|Operatsion foyda normasi MGX (Metagenomi, Inc)|DTIL: Operatsion marja|GBIO: Operatsion foyda koeffitsiyenti|Operatsion rentabellik Boundless Bio Inc.|Sotuvning operatsion marjasi Exicure (XCUR)|Operatsion marja IMNN|PHIO (Phio Pharmaceuticals Corp.) - Operatsion foyda normasi|Mustang Bio, Inc. - Sotuvning operatsion marjasi|RNAZ - Sotuvning operatsion marjasi|BNGO: Sotuvning operatsion marjasi|APDN (Applied DNA Sciences Inc) - Operatsion foyda bo'yicha sotuv rentabelligi|BLUE (Bluebird Bio) - Sotuvning operatsion marjasi|ImmunoPrecise Antibodies Ltd - Operatsion foyda normasi|OMGA (Omega Therapeutics Inc) - Operatsion marja|Operatsion rentabellik OMIC|Operatsion rentabellik Regulus Therapeutics Inc. (RGLS)|Sotuvning operatsion marjasi Syros Pharmaceuticals, Inc. SYRS|Telesis Bio - Sotuvning operatsion marjasi|Operatsion foyda normasi TCON|UBX - Operatsion rentabellik